These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22067939)

  • 1. Beneficial effect of probiotics in IBD: are peptidogycan and NOD2 the molecular key effectors?
    Macho Fernandez E; Pot B; Grangette C
    Gut Microbes; 2011 Sep; 2(5):280-6. PubMed ID: 22067939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide.
    Macho Fernandez E; Valenti V; Rockel C; Hermann C; Pot B; Boneca IG; Grangette C
    Gut; 2011 Aug; 60(8):1050-9. PubMed ID: 21471573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of intestinal homeostasis and immunity with probiotic lactobacilli.
    van Baarlen P; Wells JM; Kleerebezem M
    Trends Immunol; 2013 May; 34(5):208-15. PubMed ID: 23485516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of action of probiotics.
    Boirivant M; Strober W
    Curr Opin Gastroenterol; 2007 Nov; 23(6):679-92. PubMed ID: 17906447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in translational research on probiotic lactobacilli: from in vitro assays to clinical trials.
    Meijerink M; Mercenier A; Wells JM
    Benef Microbes; 2013 Mar; 4(1):83-100. PubMed ID: 23434949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer.
    Matsumoto S; Hara T; Nagaoka M; Mike A; Mitsuyama K; Sako T; Yamamoto M; Kado S; Takada T
    Immunology; 2009 Sep; 128(1 Suppl):e170-80. PubMed ID: 19740306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probiotics in inflammatory bowel disease: possible mechanisms of action.
    Dotan I; Rachmilewitz D
    Curr Opin Gastroenterol; 2005 Jul; 21(4):426-30. PubMed ID: 15930982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding why probiotic therapies can be effective in treating IBD.
    Fedorak RN
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S111-5. PubMed ID: 18806699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health, probiotics, and inflammation.
    Mengheri E
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S177-8. PubMed ID: 18685508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Probiotics for inflammatory bowel disease].
    Iizuka H; Takaishi H; Hibi T
    Nihon Rinsho; 2005 May; 63(5):776-80. PubMed ID: 15881169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactobacilli as multifaceted probiotics with poorly disclosed molecular mechanisms.
    Turpin W; Humblot C; Thomas M; Guyot JP
    Int J Food Microbiol; 2010 Oct; 143(3):87-102. PubMed ID: 20801536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of gut microbiota in mediating the effect of NOD2 defects in inflammatory bowel disease.
    Rogler G
    Gut; 2010 Feb; 59(2):153-4. PubMed ID: 20176638
    [No Abstract]   [Full Text] [Related]  

  • 13. Glycan sequence-dependent Nod2 activation investigated by using a chemically synthesized bacterial peptidoglycan fragment library.
    Wang N; Huang CY; Hasegawa M; Inohara N; Fujimoto Y; Fukase K
    Chembiochem; 2013 Mar; 14(4):482-8. PubMed ID: 23362105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactobacillus plantarum lipoteichoic acid down-regulated Shigella flexneri peptidoglycan-induced inflammation.
    Kim HG; Lee SY; Kim NR; Lee HY; Ko MY; Jung BJ; Kim CM; Lee JM; Park JH; Han SH; Chung DK
    Mol Immunol; 2011 Jan; 48(4):382-91. PubMed ID: 21129777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotics in inflammatory bowel disease--therapeutic rationale and role.
    Shanahan F
    Adv Drug Deliv Rev; 2004 Apr; 56(6):809-18. PubMed ID: 15063591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOD1 and NOD2 receptors: integral members of the innate and adaptive immunity system.
    Antosz H; Osiak M
    Acta Biochim Pol; 2013; 60(3):351-60. PubMed ID: 23901396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunology and probiotic impact of the newborn and young children intestinal microflora.
    Bezirtzoglou E; Stavropoulou E
    Anaerobe; 2011 Dec; 17(6):369-74. PubMed ID: 21515397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics and immune regulation of inflammatory bowel diseases.
    Cong Y; Konrad A; Iqbal N; Elson CO
    Curr Drug Targets Inflamm Allergy; 2003 Jun; 2(2):145-54. PubMed ID: 14561167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nod2: The intestinal gate keeper.
    Al Nabhani Z; Dietrich G; Hugot JP; Barreau F
    PLoS Pathog; 2017 Mar; 13(3):e1006177. PubMed ID: 28253332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inflammatory bowel diseases: an immunological approach].
    Sepúlveda SE; Beltrán CJ; Peralta A; Rivas P; Rojas N; Figueroa C; Quera R; Hermoso MA
    Rev Med Chil; 2008 Mar; 136(3):367-75. PubMed ID: 18575665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.